Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | MST1R | Q04912 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | HGF | P14210 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | CSF1R | P07333 | 4/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435587 | 0.95 | MET (0.41) | METLCKKDRMST1RAURKA | |
| SCHEMBL13462897 | 0.88 | CSF1R (0.39) | METLCKKDRMST1RAURKA | |
| SCHEMBL3559873 | 0.87 | MET (0.48) | METLCKKDRMST1RAURKA | |
| SCHEMBL16083963 | 0.83 | MET (0.43) | METLCKKDRMST1RAURKA | |
| SCHEMBL16083969 | 0.81 | MET (0.49) | METLCKKDRMST1RAURKA | |
| SCHEMBL3558835 | 0.80 | MET (0.43) | METLCKKDRMST1RAURKA | |
| SCHEMBL16076007 | 0.80 | MET (0.44) | METLCKKDRMST1RAURKA | |
| SCHEMBL3562448 | 0.80 | BRAF (0.43) | METLCKKDRMST1RAURKA | |
| SCHEMBL3560357 | 0.80 | MET (0.66) | METKDRMST1RHGFRPS6KB1 | |
| SCHEMBL16076011 | 0.79 | KDR (0.43) | METLCKKDRMST1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2125781-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214544-A1 | Substituted heterocycles and methods of use | HGF, MET, HGFAC | MET 2/4885LCK 860/4885KDR 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.